Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Equity Capital Markets

Acotec Scientific / Equity Capital Markets

Acotec, a leading China-based peripheral-vascular interventional device company, is looking to raise up to USD 300m via a Hong Kong listing.  In this note, we look at two core drug coated balloon products of the company, namely the AcoArt Orchid &amp; Dhalia for the above the knee artery stenosis and AcoArt Tulip &amp; Litos for the below the knee stenosis. Both AcoArt Orchid &amp; Dhalia, and AcoArt Tulip &amp; Litos reported efficacy that could be potentially better than its benchmark product. Thanks to its early mover advantage, the AcoArt Orchid &amp; Dhalia had a dominant market share. The main growth driver of the company's core product will be increasing penetration rate and indication expansion. Besides the DCB products, we think the company's product pipeline is not exciting. The company has a good management team but the pre-IPO investors are overall mediocre.

Acotec, a leading China-based peripheral-vascular interventional device company, is looking to raise up to USD 300m via a Hong Kong listing.  In this note, we look at two core drug coated balloon products of the company, namely the AcoArt Orchid &amp; Dhalia for the above the knee artery stenosis and AcoArt Tulip &amp; Litos for the below the knee stenosis. Both AcoArt Orchid &amp; Dhalia, and AcoArt Tulip &amp; Litos reported efficacy that could be potentially better than its benchmark product. Thanks to its early mover advantage, the AcoArt Orchid &amp; Dhalia had a dominant market share. The main growth driver of the company's core product will be increasing penetration rate and indication expansion. Besides the DCB products, we think the company's product pipeline is not exciting. The company has a good management team but the pre-IPO investors are overall mediocre.

Acotec (先瑞达) Pre-IPO: Early Mover Advantage in Peripheral DCB

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

With the acceleration of the aging process, the prevalence of various vascular diseases continue to rise, and related medical needs have increased dramatically. Among them, interventional therapy has been highly recognized by clinicians and patients with its advantages of less trauma, fewer complications, high safety and less patient pain, and the market demand shows a rapid growth. Therefore, many domestic innovative medical device enterprises accelerated the pace of listing in order to seize more market share. For example, according to the disclosure of the HKEX, <a href="https://www.smartkarma.com/entities/acotec-scientific-holdings-limited" target="_blank" data-smartkarma-citation="entities:32176:1" rel="noopener">Acotec Scientific Holdings (ASH HK)</a> applied to be listed on the main board on February 11, 2021. The following mainly include the insights on business, industry and financial position.

With the acceleration of the aging process, the prevalence of various vascular diseases continue to rise, and related medical needs have increased dramatically. Among them, interventional therapy has been highly recognized by clinicians and patients with its advantages of less trauma, fewer complications, high safety and less patient pain, and the market demand shows a rapid growth. Therefore, many domestic innovative medical device enterprises accelerated the pace of listing in order to seize more market share. For example, according to the disclosure of the HKEX, Acotec Scientific Holdings (ASH HK) applied to be listed on the main board on February 11, 2021. The following mainly include the insights on business, industry and financial position.

Pre-IPO Acotec Scientific Holdings - First-Mover Advantage Together with Challenges

China

Acotec Scientific is a medical technology company specializing in the research, development, and application of innovative solutions for vascular diseases. Its core products include drug-coated balloons (DCB) and percutaneous transluminal angioplasty (PTA) balloon catheters, such as AcoArt Orchid & Dhalia. The company was founded in 2008 and is headquartered in Beijing, China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Acotec Scientific (6669 HK)

Acotec (先瑞达) Pre-IPO: Early Mover Advantage in Peripheral DCB

Acotec is early in the peripheral artery drug coated balloon device market with a dominant market share for above-the-knee stenosis. Having said...

Ke Yan, CFA, FRM

Pre-IPO Acotec Scientific Holdings - First-Mover Advantage Together with Challenges

This article analyzed Acotec Scientific in terms of its business, industry characteristics, financial position, and also include the concerns and...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)